Innovent Biologics, Inc. announced updated Phase 1 clinical data for IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3, in patients with relapsed or refractory multiple myeloma ...

(PASI) score achieved in mild-to-moderate plaque psoriasis patients with once-daily 200 mg 28-day treatment. - Steady-state elimination half-life after 28-day treatment in patients was 6.5 days, ...

Based on an integrated analysis of the efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) data from dose optimization cohorts receiving IBI3003 at 120, 360, and 540 µg/kg in the Phase 1 ...

FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases HONG KONG and SHANGHAI and ...

OpenAI-backed Nabla Bio's JAM-2 AI model designs antibodies ready for human trials, potentially revolutionizing drug ...

Peanut allergy is one of the most serious food allergies and can lead to sudden, life-threatening reactions. Researchers from ...

Lung cancer remains the deadliest malignancy worldwide, and non-small cell lung cancer (NSCLC) accounts for roughly 85 ...

Blood plasma has long been the workhorse of clinical diagnostics, a fluid so rich in molecular information that a single draw ...

Earendil Labs announced on September 24, 2026, a research collaboration with Genentech, a member of the Roche Group, to discover and develop multiple bispecific antibody therapies for cancer. The ...

Fast Track Designation granted for treatment of osteosarcoma Orphan Drug Designation granted for treatment of soft tissue sarcoma Multiple FDA ...

Antibody expression: Tsingke works with multiple antibody formats, including scFv, VHH, Fab, and full-length IgG. Its high-throughput workflow can process up to 1,500 candidates per day, with ...

Envisagenics’ AI-powered SpliceCore® platform opens up alternative RNA splicing – one of the last largely untapped sources of tumor-specific ...